Axovant Archives -

Close Up Of Senior Man Suffering With Parkinsons Diesease

Axovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from

Axovant pushes on with Parkinson’s gene therapy, despite investor cynicism

https://pharmaphorum.com/news/axovant-pushes-on-with-parkinsons-gene-therapy/

News/ News/ R&D/ Top stories

Axovant axes neuroscience drug, focuses on gene therapies

Richard Staines Axovant, R&D 0 Comment

Swiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial,

Axovant axes neuroscience drug, focuses on gene therapies

https://pharmaphorum.com/news/axovant-axes-neuroscience-drug-focuses-on-gene-therapies/

Market Access/ News/ News/ News/ R&D/ R&D/ Top stories

Axovant CEO David Hung quits after Alzheimer’s drug failure

Richard Staines Alzheimer's, Axovant, neurology, R&D, Roivant 0 Comment

Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.

Axovant CEO David Hung quits after Alzheimer’s drug failure

https://pharmaphorum.com/news/axovant-ceo-hung-quits-alzheimers-drug-failure/

News/ News/ R&D/ Top stories/ US

Bad week for dementia R&D after Axovant howler and another failed trial

Richard Staines Alzheimer's, Axovant, dementia, JP Morgan 2018, Lundbeck, neurology, Pfizer 0 Comment

Axovant misreports trial results, Lundbeck Alzheimer’s drug fails

Bad week for dementia R&D after Axovant howler and another failed trial

https://pharmaphorum.com/news/bad-week-dementia-rd-axovant-howler-another-failed-trial/

News/ R&D

Axovant axes dementia drug after disastrous trial results

Richard Staines Axovant, GlaxoSmithKline, neurology, R&D 0 Comment

Intepirdine seemed to make symptoms worse in Lewy body disease

Axovant axes dementia drug after disastrous trial results

https://pharmaphorum.com/news/axovant-axes-development-dementia-drug/

News/ R&D

Alzheimer’s failure bursts Axovant’s bubble

Richard Staines Alzheimer's neurology, Axovant, Biotech, David Hung, GlaxoSmithKline, R&D 0 Comment

Shares fall off a cliff after intepirdine fails to produce results.

Alzheimer’s failure bursts Axovant’s bubble

https://pharmaphorum.com/news/axovants-intepirdine-fails-alzheimers-trial/

News/ UK & Europe

Fast track for dementia drug good news for Axovant and new CEO

Andrew McConaghie Axovant, David Hung, dementia, FDA fast track 0 Comment

Axovant has gained FDA fast track designation for its pipeline drug nelotanserin, a treatment for visual hallucinations suffered

Fast track for dementia drug good news for Axovant and new CEO

https://pharmaphorum.com/news/fast-track-dementia-drug-good-news-axovant-new-ceo/

News/ R&D/ US

After attracting star CEO Hung, Axovant looks to raise $125m

Andrew McConaghie Alzheimer's, Axovant, dementia 0 Comment

Axovant Sciences is maintaining its momentum following the appointment of star biotech leader David Hung earlier this week

After attracting star CEO Hung, Axovant looks to raise $125m

https://pharmaphorum.com/news/attracting-star-ceo-hung-axovant-looks-raise-125m/

Trending

Axovant

Login